Patient & Visitor InformationContact Us
  • Absorb III

  • The purpose of this study is to assess the safety and effectiveness of treating blockages in the coronary (heart) arteries (blood vessels) with an investigational (experimental) device called Absorb™ Bioresorbable Vascular Scaffold (BVS) System (the “Absorb BVS”), compared to a commercially approved metallic stent coated with medication (drug-eluting stent) called XIENCE V® Everolimus Eluting Coronary Stent System.

    XIENCE and Absorb BVS both use the drug everolimus. Everolimus helps to prevent the heart artery from re-narrowing. This re-narrowing is caused by re-growth of certain muscle cells inside the artery wall. Everolimus may stop cells in the artery wall from growing too much and therefore reduce the chance of artery re-narrowing.

    The investigational device (study device) used in this study, Absorb BVS, is a temporary device which functions like a drug-eluting stent, but is not made out of metal. Instead it consists of a plastic scaffold made out of materials that over time will gradually break down and be resorbed into the artery wall leaving behind no permanent implant.

    For more information, please contact:

    Cardiovascular Research

    The Miriam Hospital     
    Lori-Ann DeSimone
    401-793-4105

    Rhode Island Hospital
    Cardiac Projects Office 
    401-444-5324